Tecentriq 1,200 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQPV5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $39,820
Award facts
- Contract value 100% obligated
- $39,820.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $39,820.38 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Tecentriq (atezolizumab) 1,200 mg/20 mL vials. This firm fixed-price delivery order, issued on December 4, 2025, with an ultimate completion date of December 26, 2025, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The place of performance is Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its operations as a critical supplier within the federal pharmaceutical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy awarded November 13, 2025. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities globally. DMS Pharmaceutical Group's established performance on numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FQPV5?
SPE2DR26FQPV5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FQPV5 worth?
The government has obligated $39,820 on SPE2DR26FQPV5.
Is contract SPE2DR26FQPV5 an order under another contract?
Yes. SPE2DR26FQPV5 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQPV5 competed?
The extent of competition for SPE2DR26FQPV5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award